Global Biosimilar Market 2010-2014 by InfinitiResearch

VIEWS: 33 PAGES: 29

TechNavio’s analysts forecast the Global Biosimilar market to grow at a CAGR of 52.2 percent over the period 2010–2014. One of the key factors contributing to this market growth is the rise in patent expirations of branded biopharmaceuticals. The Global Biosimilar market has also been witnessing the trend of outsourcing of biosimilar manufacturing to Asian countries. However, the risk of drug development failure could pose a challenge to the growth of this market.

TechNavio’s report, the Global Biosimilar Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biosimilar market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Sandoz International GmbH, Teva Pharmaceutical, Industries Ltd., Hospira Inc., and Mylan Inc.

Key questions answered in this report
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?

More Info
									2010-2014   Global Biosimilar Market




                             technavio insights
2010-2014                     Global Biosimilar Market




            CONTENTS


            01. Executive Summary ..............................................1

            02. Introduction ...........................................................2

            03. Market Coverage .................................................4

            04. Market Landscape ................................................5

            05. Vendor Landscape ...............................................8

            06. Buying Criteria .....................................................10
            07. Market Growth Drivers ........................................11

            08. Drivers and their Impact .....................................13

            09. Market Challenges .............................................14

            10. Market Trends ......................................................16

            11. Key Vendor Analysis ...........................................18
            11.1 Sandoz International GmbH .............................................. 18

            11.2 Teva Pharmaceutical Industries Ltd. ................................ 20

            11.3 Hospira Inc............................................................................ 21

            11.4 Mylan Inc. ............................................................................. 23

            12. Other Reports in this Series .................................25




2010-2014                                                                 Global Biosimilar Market
2010-2014                Global Biosimilar Market




            EXHIBITS

            Exhibit 1: Global Biosimilar Market 2010–2014 (US$ million) .............5

            Exhibit 2: Global Biosimilar Market by Geographical
                       Segmentation 2010 ..............................................................6

            Exhibit 3: Global Biosimilar Market by Vendor
                       Segmentation 2010 ..............................................................9




2010-2014                                                            Global Biosimilar Market
Global Biosimilar Market                                                                               1

      01. Executive Summary
                             2010: US$520 million
        Market Size
                             2014: US$2,256 million

        Growth Rate          CAGR 52.2 percent

                             The Americas
        Key Geographies      EMEA
                             APAC

                             Patients
        Key Customer
                             Hospitals
        Segments
                             Diagnostic Centers

                             Outsourcing of Biosimilar Manufacturing
        Trends               Mergers and Acquisitions
                             Huge Investments in R&D

                             Rise in Patent Expirations
                             Cost-effective Treatment
        Drivers              Favorable Government         Regulations   in   Several   European
                             Countries
                             Rising Aging Population

                             Risk of Drug Failure
                             Reluctance to Prescribe Biosimilar Products
        Challenges
                             Limited Availability of Biosimilar Products
                             Uncertainty about Government Regulations

                             Cost
        Key Customer Needs   Effectiveness and Safety
                             Availability

                             Sandoz International GmbH
                             Teva Pharmaceutical Industries Ltd.
        Key Vendors
                             Hospira Inc.
                             Mylan Inc.




2010-2014                                                                       Global Biosimilar Market
Global Biosimilar Market                                                                                      2

      02. Introduction
      Biosimilar, or follow-on biologic (FOB), is a biotechnological product that has proved to be
      comparable in quality to an already approved reference product by both non‐clinical and
      clinical evaluations. It is essentially similar to a reference biopharmaceutical product with
      respect to quality, safety, and efficacy. Biosimilars are legally approved subsequent versions of
      innovator biopharmaceutical products, following the latter's patent expiry. It should be noted
      that a biosimilar is similar, but not identical, to a reference biopharmaceutical product. A
      biosimilar is developed after the expiry of the patent for a similar generic chemical product.
      However, a biosimilar is still fundamentally different from the generic chemical prod
								
To top